BOULDER, Colo., July 27, 2016 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2016 and hold a conference call to discuss those results on Thursday, August 4, 2016. Ron Squarer, Chief Executive Officer, will lead the call.
About Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Six registration studies are currently advancing related to three cancer drugs. These programs include binimetinib (MEK162), encorafenib (LGX818) and selumetinib (AstraZeneca). For more information on Array, please go to www.arraybiopharma.com.